A Phase 4 interventional study of Early Dual IV Antibiotic Therapy - MRSA and Early Dual IV Antibiotic Therapy - MSSA in Staphylococcus Aureus Bacteremia, sponsored by West Virginia University. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by West Virginia University · Phase 4, Interventional, and Treatment
The goal of this open-label, pragmatic, randomized controlled clinical trial is to learn if patients with Staphylococcus aureus bacteremia (SAB) given the intervention of early dual intravenous (IV) antibiotic therapy will decrease duration of bacteremia (\< 6 days) and improve outcomes compared to single IV antibiotic therapy.
The main questions this study aims to answer are:
Participants will be asked to agree to be randomized (like flipping a coin) to receive two or one IV antibiotic(s). Once the infection has cleared, the treatment will be changed to PO antibiotics. As part of usual care, participants will have weekly lab tests for monitoring while on antibiotics, receive a telephone call to see how the participants are doing, and follow up in person or by telephone or video in Infectious Diseases (ID) Clinic. Participant participation will last 12 weeks after the participant is discharged from the hospital.
297 studies on the registry are indexed under Bacteremia; 51 are open to participants now.
This study's planned enrollment of 300 is above the median of 156 across 156 interventional studies indexed under Bacteremia.
Browse Bacteremia studies →West Virginia University is the lead sponsor of 157 studies on the registry; 36 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once type of Staphylococcus aureus bacteremia (MRSA vs. MSSA) is determined the following IV antibiotics will be given: * MRSA - daptomycin plus ceftaroline; * MSSA - cefazolin plus ertapenem; * MRSA or MSSA - rifampin PO may be added for patients with prosthetic material
Drug: Early Dual IV Antibiotic Therapy - MRSA · Drug: Early Dual IV Antibiotic Therapy - MSSA
Once type of Staphylococcus aureus bacteremia (MRSA vs. MSSA) is determined the following IV antibiotics will be given: * MRSA - daptomycin, vancomycin, or ceftaroline; * MSSA - cefazolin, oxacillin, or nafcillin; * MRSA or MSSA - rifampin PO may be added for patients with prosthetic material
Drug: Single Agent IV Antibiotic Therapy - MRSA · Drug: Single Agent IV Antibiotic Therapy - MSSA
Participant given IV daptomycin plus ceftaroline dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
Also known as: daptomycin, ceftaroline, rifampin
Participant given IV cefazolin plus ertapenem dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
Also known as: cefazolin, ertapenem, rifampin
Participant given one of the following IV therapies: daptomycin, vancomycin, or ceftaroline. Oral rifampin may be added for participants with prosthetic material.
Also known as: daptomycin, vancomycin, ceftaroline, rifampin
Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin. Oral rifampin may be added for participants with prosthetic material.
Also known as: cefazolin, oxacillin, nafcillin, rifampin
Percentage of participants with prolonged bacteremia (≥ 6 days)
Percentage of participants with prolonged bacteremia (≥ 6 days) up to 12 weeks post hospital discharge.
Time frame: Up to 12 weeks post hospital discharge
Seeding of a New Site - Incidence
Incidence of new infection of heart valve, joint, or spine up to 12 weeks post hospital discharge.
Time frame: Up to 12 weeks post hospital discharge
All-Cause Mortality
Number of participants who died from any cause up to 12 weeks post hospital discharge.
Time frame: Up to 12 weeks post hospital discharge
Number of patients with cure/control
Number of patients with cure/control using clinical (resolution of infection - e.g., wound healed) and laboratory (improvement in inflammatory markers - e.g., CRP normalization) parameters.
Time frame: Up to 12 weeks post hospital discharge
Time to Positivity (TTP)
Time in hours from first set of blood culture bottle on laboratory instrument to positive culture bottle off laboratory instrument (TTP1).
Time frame: Up to 14 days post hospital admission
Sequential Time to Positivity (STTP)
Ratio of the Time to Positivity of the second set of blood cultures divided by the first set of blood cultures (TTP2/TTP1).
Time frame: Up to 14 days post hospital admission
Length of Hospital Stay
Duration in days from hospital admission to hospital discharge.
Time frame: Up to 12 weeks post hospital discharge
Overall Hospital Readmission
Number of participants readmitted for any reason up to 12 weeks after discharge from the hospital.
Time frame: Up to 12 weeks post hospital discharge
Rate of Relapsed Bacteremia
Recurrence of bacteremia with the same organism one week after initial clearance.
Time frame: Up to 12 weeks post hospital discharge
Time to First Negative Blood Culture
Time from hospital admission to the first documented negative blood culture.
Time frame: Up to 14 days post hospital admission
Incidence of Antibiotic-Associated Side Effects and Toxicity
Occurrence of adverse events related to antibiotic therapy, including Clostridioides difficile infection, as assessed by clinical evaluation and laboratory testing.
Time frame: Up to 12 weeks post hospital discharge
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daptomycin · Cefazolin